SS-31: A promising therapeutic agent against bleomycin-induced pulmonary fibrosis in Mice
The mitochondria-targeting drug SS-31 exhibited potential in mitigating bleomycin-induced pulmonary fibrosis, improving mitochondrial structural and functional damage, stabilizing the balance between oxidative and antioxidant systems, reducing inflammatory factor expression, and improving apoptosis in lung tissue.
Authors
- Xianglin Meng (ORCID: https://orcid.org/0000-0001-5091-3260)
- Qilao Gu (ORCID: https://orcid.org/0000-0002-2826-1902)
- Wei Yang (ORCID: https://orcid.org/0009-0000-7388-5354)
- Mingyan Zhao (ORCID: https://orcid.org/0000-0003-2814-1262)
- Haichao Zhang (ORCID: https://orcid.org/0000-0003-0154-2947)
- Yunlong Wang (ORCID: https://orcid.org/0009-0004-7557-6263)
Institutions
- Harbin Medical University (CN)
- Heilongjiang Provincial Hospital (CN)
- Education Department of Heilongjiang Province (CN)
- First Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1371/journal.pone.0315473
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China